NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) released its earnings results on Wednesday, November, 6th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

5 analysts have issued 1-year price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $40.00 to $65.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $50.40 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Press coverage about CNST stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 1,920,000 shares, an increase of 34.3% from the November 14th total of 1,430,000 shares. Based on an average daily volume of 517,400 shares, the days-to-cover ratio is presently 3.7 days. Currently, 16.2% of the company's shares are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Intercept Pharmaceuticals (ICPT), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Blueprint Medicines (BPMC), Evotec (EVTCY), Alkermes (ALKS), SAGE Therapeutics (SAGE), Myokardia (MYOK) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Biogen (BIIB), Lam Research (LRCX), Alibaba Group (BABA), Chipotle Mexican Grill (CMG), Adobe (ADBE), Baidu (BIDU), NVIDIA (NVDA), Roku (ROKU), Goldman Sachs Group (GS) and Snap (SNAP).

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.75%), P.A.W. Capital Corp (0.62%), Alps Advisors Inc. (0.20%) and Barclays PLC (0.02%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Barclays PLC and State Street Corp. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Of The University Of C Regents and Patrick Trojer. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $38.14.

Constellation Pharmaceuticals has a market capitalization of $1.28 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]